Auberger P, Tamburini-Bonnefoy J, Puissant A (2020) Drug resistance in hematological malignancies. Int J Mol Sci 21(17):6091

Article  PubMed  PubMed Central  Google Scholar 

Bhansali RS, Pratz KW, Lai C (2023) Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol 16(1):29

Article  PubMed  PubMed Central  Google Scholar 

Im A, Pavletic SZ (2017) Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol 10(1):94

Article  PubMed  PubMed Central  Google Scholar 

Ivanov AV, Alecsa SM, Popescu R, Starcea MI, Mocanu AM, Rusu C, Miron IC (2023) Pediatric acute lymphoblastic leukemia emerging therapies-from pathway to target. Int J Mol Sci 24(5):4661

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velasquez MP, Bonifant CL, Gottschal S (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131(1):30–38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goebeler ME, Bargou RC (2020) T cell-engaging therapies-BiTEs and beyond. Nat Rev Clin Oncol. 17(7):418–434

Article  PubMed  Google Scholar 

Epperly R, Gottschalk S, Velasquez MP (2020) Harnessing T cells to target pediatric acute myeloid leukemia: CARs, BiTEs, and Beyond. Children (Basel) 7(2):14

PubMed  Google Scholar 

Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W (2003) Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci 94(8):655–667

Article  CAS  PubMed  Google Scholar 

Gao J, Zheng Q, Xin N, Wang W, Zhao C (2017) CD155, an onco-immunologic molecule in human tumors. Cancer Sci 108(10):1934–1938

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donnell JS, Madore J, Li XY, Smyth MJ (2020) Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 65(1):189–196

Article  PubMed  Google Scholar 

Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y (2021) Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res 40(1):267

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Cinzia F, Cippitelli M, Gismondi A, Santoni A, Paolini R (2020) CD155: a multi-functional molecule in tumor progression. Int J Mol Sci 21(3):922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T (2020) CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T Cells. Immunity 53(4):805–823

Article  CAS  PubMed  Google Scholar 

Zhang H, Yang Z, Du G, Cao L, Tan B (2021) CD155-prognositic and immunotherapeutic implications based on multiple analyses of databased across 33 human cancers. Technol Cancer Res Treat 20(1):1–12

Google Scholar 

Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, Yoshikawa H, Hara H, Shibuya A, Shibuya K (2016) Increased soluble CD155 in serum of cancer patients. PLoS ONE 11(4):e0152982

Article  PubMed  PubMed Central  Google Scholar 

Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H (2016) T-Cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22(12):3057–3066

Article  CAS  PubMed  Google Scholar 

Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A (2018) Key role of the CD56lowCD16low Natural killer cell subset in the recognition and killing of multiple myeloma cells. Cancers 10(12):473

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90(1):109–115

Article  CAS  PubMed  Google Scholar 

Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Santos CD, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W (2018) Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene 37(39):5269–5280

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaito Y, Hirano M, Futami M, Nojima M, Tamura H, Tojo A, Imai Y (2022) CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. Oncol Lett 23(2):51

Article  CAS  PubMed  Google Scholar 

Ma W, Ma J, Lei T, Zhao M, Zhang M (2019) Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody. J Cancer 10(21):5153–5161

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao H, Ma J, Lei T, Ma W, Zhang M (2019) The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. Invest New Drugs 37(5):810–817

Article  CAS  PubMed  Google Scholar 

Sun X, Yu Y, Ma L, Xue X, Gao Z, Ma J, Zhang M (2020) T cell cytotoxicity toward hematologic malignancy via B7–H3 targeting. Invest New Drugs 38(3):722–732

Article  PubMed  Google Scholar 

Sun X, Zhao J, Ma L, Sun X, Ge J, Yu Y, Ma J, Zhang M (2021) B7–H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells. Invest New Drugs 39(1):24–33

Article  CAS  PubMed  Google Scholar 

Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M (2022) TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21(1):185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huehls AM, Coupet TA, Sentman C (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93(3):290–296

Article  CAS  PubMed  Google Scholar 

Cassioli C, Baldari CT (2022) The expanding arsenal of cytotoxic T cells. Front Immunol 13:883010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian Z, Liu M, Zhang Y, Wang X (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 14(1):75

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang M, Sharma V, Mendelsohn A, Wei Q, Li Ji YuB, Larrick JW, LUM LG (2022) Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumour. Ann Med 54(1):1047–1057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubicka E, Lum LG, Huang M, Thakur A (2022) Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Front Immunol 13:899468

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X (2019) Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol 12(1):59

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen C, Guo Q, Fu H, Yu J, Wang L, Sun Y, Zhang J, Duan Y (2021) Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials 275:120988

Article  CAS  PubMed  Google Scholar 

Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, Li XY (2022) CD155 in tumor progression and targeted therapy. Cancer Lett 545(10):215830

Article  CAS  PubMed  Google Scholar 

Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. Blood 113(15):3503–3511

Article  CAS  PubMed